Results 11 to 20 of about 137,029 (384)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Frontiers in Pharmacology, 2020
ObjectiveTo compare the market dynamics of biosimilar infliximab among four Organization for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and Korea) where supply-side and demand-side policies varied greatly, given high and ...
Yujeong Kim, Hye-Young Kwon, Hye-Young Kwon, Brian Godman, Brian Godman, Brian Godman, Evelien Moorkens, Steven Simoens, SeungJin Bae   +8 more
doaj   +2 more sources

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial

Scientific Reports, 2018
We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG.
Masaaki Mori, Takuma Hara, Masako Kikuchi, Hiroyuki Shimizu, Tomoyuki Miyamoto, Satoru Iwashima, Tatsuya Oonishi, Kunio Hashimoto, Norimoto Kobayashi, Kenji Waki, Yasuo Suzuki, Yoshikazu Otsubo, Hiroshi Yamada, Chikao Ishikawa, Taichi Kato, Shigeto Fuse   +15 more
doaj   +2 more sources

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent [PDF]

, 2001
Background Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF-α in
Joseph Keane, Sharon K. Gershon, Robert P. Wise, Elizabeth Mirabile‐Levens, John Kasznica, William D. Schwieterman, Jeffrey Siegel, M. Miles Braun   +7 more
openalex   +2 more sources

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Gut, 2021
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated ...
N. Kennedy, Simeng Lin, J. Goodhand, N. Chanchlani, B. Hamilton, C. Bewshea, R. Nice, D. Chee, J. Cummings, A. Fraser, P. Irving, N. Kamperidis, K. Kok, C. Lamb, J. Macdonald, S. Mehta, R. Pollok, T. Raine, Philip J. Smith, A. Verma, S. Jochum, T. Mcdonald, S. Sebastian, C. Lees, N. Powell, T. Ahmad   +25 more
semanticscholar   +1 more source

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Gut, 2021
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections.
N. Kennedy, J. Goodhand, C. Bewshea, R. Nice, D. Chee, Simeng Lin, N. Chanchlani, J. Butterworth, R. Cooney, N. Croft, A. Hart, P. Irving, K. Kok, C. Lamb, J. Limdi, J. Macdonald, D. McGovern, S. Mehta, C. Murray, K. Patel, R. Pollok, T. Raine, R. Russell, C. Selinger, Philip J. Smith, J. Bowden, T. Mcdonald, C. Lees, S. Sebastian, N. Powell, T. Ahmad   +30 more
semanticscholar   +1 more source

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study

Journal of Crohn's & Colitis, 2022
Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently been shown to be as effective as IV infliximab after two doses of IV ...
Philip J. Smith, Lisa Critchley, D. Storey, B. Gregg, J. Stenson, A. Kneebone, Tracy Rimmer, Stevena Burke, Shamas Hussain, W. Teoh, S. Vazeille, S. Serna, A. Steel, E. Derbyshire, P. Collins, M. Dibb, P. Flanagan, C. Probert, A. Verma, S. Subramanian   +19 more
semanticscholar   +1 more source

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum drug levels, has been proposed as an alternative to standard therapy to optimize efficacy and safety of infliximab and ...
S. W. Syversen, K. Jørgensen, G. Goll, M. K. Brun, Ø. Sandanger, K. Bjørlykke, J. Sexton, Inge Christoffer Olsen, J. Gehin, D. Warren, R. Klaasen, G. Noraberg, T. J. Bruun, C. Dotterud, M. Ljoså, A. Haugen, Rune Johan Njålla, C. Zettel, C. Ystrøm, Y. Bragnes, S. Skorpe, T. Thune, K. A. Seeberg, B. Michelsen, I. Blomgren, E. K. Strand, P. Mielnik, R. Torp, C. Mork, T. Kvien, J. Jahnsen, N. Bolstad, E. Haavardsholm   +32 more
semanticscholar   +1 more source

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and ...
S. W. Syversen, G. Goll, K. Jørgensen, Ø. Sandanger, J. Sexton, Inge Christoffer Olsen, J. Gehin, D. Warren, M. K. Brun, R. Klaasen, L. Karlsen, G. Noraberg, C. Zettel, M. Ljoså, A. Haugen, Rune Johan Njålla, T. J. Bruun, K. A. Seeberg, B. Michelsen, E. K. Strand, S. Skorpe, I. Blomgren, Y. Bragnes, C. Dotterud, T. Thune, C. Ystrøm, R. Torp, P. Mielnik, C. Mork, T. Kvien, J. Jahnsen, N. Bolstad, E. Haavardsholm   +32 more
semanticscholar   +1 more source

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Journal for ImmunoTherapy of Cancer, 2021
Background Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases.
Fangwen Zou, D. Faleck, A. Thomas, Jessica P Harris, D. Satish, Xuemei Wang, A. Charabaty, M. Ernstoff, Isabella C. Glitza Oliva, S. Hanauer, J. McQuade, M. Obeid, A. Shah, D. Richards, E. Sharon, J. Wolchok, John A Thompson, Yinghong Wang   +17 more
semanticscholar   +1 more source

Infliximab

TURKDERM, 2022
Infliximab is a TNF-α inhibitor in the form of a chimeric monoclonal antibody. It received FDA approval in 2006 for the treatment of adult patients with severe chronic plaque psoriasis who developed side effects with conventional therapies or in whom these therapies were contraindicated or did not produce any response.
openaire   +3 more sources